Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 6/20 | 0.51 |
| ▸ | PTGS2 | P35354 | 6/20 | 0.51 |
| ▸ | MAPT | P10636 | 5/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.49 |
| ▸ | NPC1 | O15118 | 5/20 | 0.49 |
| ▸ | RAB9A | P51151 | 5/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 3/20 | 0.40 |
| ▸ | NFKB2 | Q00653 | 3/20 | 0.40 |
| ▸ | RELA | Q04206 | 3/20 | 0.40 |
| ▸ | CASP3 | P42574 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29804937 | 1.00 | PTGS1 (0.51) | PTGS1PTGS2MAPTKDM4ENPC1 | |
| Dimethylformamide SCHEMBL11877509 | 0.90 | ALOX5 (0.49) | PTGS1PTGS2MAPTKDM4ENPC1 | |
| SCHEMBL7026414 | 0.81 | LMNA (0.40) | PTGS1PTGS2MAPTKDM4ENPC1 | |
| SCHEMBL25420534 | 0.81 | PTGS1 (0.48) | PTGS1PTGS2MAPTKDM4ENPC1 | |
| SCHEMBL5541284 | 0.81 | PTGS1 (0.48) | PTGS1PTGS2MAPTKDM4ENPC1 | |
| SCHEMBL10088907 | 0.79 | ALOX5 (0.40) | PTGS1PTGS2MAPTKDM4ENPC1 | |
| SCHEMBL9729620 | 0.79 | ALOX5 (0.51) | PTGS1PTGS2MAPTKDM4ENPC1 | |
| SCHEMBL17705386 | 0.77 | PTGS1 (0.51) | PTGS1PTGS2MAPTKDM4ENPC1 | |
| SCHEMBL11697820 | 0.77 | ALOX5 (0.45) | PTGS1PTGS2MAPTKDM4ENPC1 | |
| SCHEMBL8626959 | 0.75 | MEN1 (0.49) | PTGS1PTGS2MAPTKDM4ENPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120040408-A | Colorimetric-near infrared dual-detection fluorescent probe for hypochlorous acid detection and preparation method and application thereof | 镇江江南化工有限公司 | 2025-05-27 | — | — | CN | claimed |
| CN-115636808-B | Chromone-benzoyl hydrazone alpha-glucosidase inhibitor and preparation method and application thereof | 贵州医科大学附属医院 | 2023-10-17 | — | — | CN | claimed |
| CN-112745310-B | Chromone 2-piperazine linked furazan derivative and preparation method and application thereof | 沈阳药科大学 | 2023-09-12 | — | — | CN | claimed |
| CN-112745309-B | Chromone 3-position nitric oxide donor derivative and preparation method and application thereof | 沈阳药科大学 | 2023-09-12 | — | — | CN | claimed |
| WO-2021176428-A1 | PHENANTHROLINE, CARBAZOLE AND FLAVYLIUM BASED CYANINES AND COMPOSITIONS AND METHODS OF MAKING AND USING THE SAME | JAWAHARLAL NEHRU CENTRE FOR ADVANCED SCIENTIFIC RESEARCH (IN) | 2021-09-10 | — | — | WO | claimed |
| CN-1554651-A | Benzopyrans and benzothiopyrans, pharmaceutical compositions containing them and process for their preparation | Ĭ��ר���ɷ�����˾ | 2004-12-15 | — | — | CN | claimed |
| US-6596758-B1 | Treatment of dislipidaemias, atherosclerosis and diabetes, to pharmaceutical compositions comprising them and to processes allowing the preparation of these compounds. | MERCK PATENT GMBH (DE) | 2003-07-22 | — | — | US | claimed |
| EP-1140893-B1 | BENZOPYRANS AND BENZOXEPINES, PHARMACEUTICAL COMPOSITIONS COMPRISING THEM AND PREPARATION PROCESS | MERCK PATENT GMBH (DE) | 2003-03-05 | — | — | EP | claimed |
| EP-4691558-A2 | TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS | University Court of The University of Dundee (GB) | 2026-02-11 | — | — | EP | disclosed |
| US-20250295789-A1 | TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS | UNIVERSITY COURT OF THE UNIVERSITY OF DUNDEE (GB) | 2025-09-25 | — | — | US | disclosed |
| EP-2857018-B1 | Treatment or prophylaxis of proliferative conditions | UNIV COURT OF THE UNIV OF DUNDEE (GB) | 2025-09-03 | — | — | EP | disclosed |
| WO-2025137442-A1 | SOLID AND SALT FORMS OF TCR-NcK MODULATORS AND USES THEREOF | ARTAX BIOPHARMA INC. (US) | 2025-06-26 | — | — | WO | disclosed |
| CN-120040408-A | Colorimetric-near infrared dual-detection fluorescent probe for hypochlorous acid detection and preparation method and application thereof | 镇江江南化工有限公司 | 2025-05-27 | — | — | CN | disclosed |
| CN-119306737-A | Benzo heterocyclic compound, pharmaceutically acceptable salt or stereoisomer thereof, and preparation method and application thereof | 江苏集萃分子工程研究院有限公司 | 2025-01-14 | — | — | CN | disclosed |
| WO-1997008193-A1 | ACYLATED OLIGOPEPTIDE DERIVATIVES HAVING CELL SIGNAL INHIBITING ACTIVITY | NOVARTIS AG (CH) | 1997-03-06 | — | — | WO | disclosed |
| US-5155130-A | Lipoxygenase inhibitors | CIBA-GEIGY CORPORATION (US) | 1992-10-13 | — | — | US | disclosed |
| US-5004744-A | Durability; effectiveness at low concentration | BAYER AKTIENGESELLSCHAFT (DE) | 1991-04-02 | — | — | US | disclosed |
| EP-0412939-A2 | Certain benzopyran and benzothiopyran derivatives | CIBA-GEIGY AG (CH) | 1991-02-13 | — | — | EP | disclosed |
| EP-0373425-A2 | Substituted pyridazinones, their preparation method and their use as insecticides | BAYER AG (DE) | 1990-06-20 | — | — | EP | disclosed |
| US-3984441-A | ANTIALLERGENS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JA) | 1976-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250295789-A1 | TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS | CYP1B1, BRCA1, UGT1A1 | PTGS1 93/4885PTGS2 175/4885MAPT 4488/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.